# US 2009/0222932 A1 · Alzheimer's disease animal model, method for obtaining same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0222932 A1
- Document ID: US20090222932A1
- Status: Published application
- Kind: A1
- Application number: 12/095,887
- Filed: 2006-12-01
- Published: 2009-09-03
- Earliest claimed: 2005-12-02
- Assignees: Universidad Autonoma De Madrid; Consejo Superior de Investigaciones Cientificas
- Inventors: Fernando Valdivieso Amate; Lluis Montoliu Jose; Julio Pozueta Larios
- Web page: https://patentgrep.com/patent/US20090222932A1

## CPC

- C07K 14/8114: {Kunitz type inhibitors}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A01K 2207/15: Humanized animals
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/0312: Animal model for Alzheimer's disease
- C12N 2800/102: for yeast
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2500/10: involving cells
- G01N 2800/2821: Alzheimer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a transgenic non-human animal which can be used as a non-human animal model for studying Alzheimer's disease (AD) and which is characterized in that: it contains a heterologous polynucleotide (transgene) which is inserted in the genome thereof and which comprises the nucleotide sequence of the complete human APP gene together with the regulatory sequences thereof; and it has an endogenous expression pattern similar to that of the hAPP gene in humans. The inventive model can be used to study AD and in the screening of potentially-useful compounds for the prevention and/or treatment of AD.

## Claims

### Claim 1

An isolated polynucleotide consisting of the nucleotide sequence comprised between nucleotide 26,064,934 and nucleotide 26,642,665 of human chromosome 21 (NCBI35:21:26064934:26642665:1) [SEQ ID NO: 74], or a fragment of said polynucleotide comprising the complete human APP gene (hAPP) together with the regulatory sequences thereof.

### Claim 2 (depends on 1)

Polynucleotide according to claim 1, wherein said complete hAPP gene together with the regulatory sequences thereof is comprised between nucleotide 26,174,733 and nucleotide 26,464,809 of human chromosome 21 (NCBI35:21:26174733:26464809:1) [SEQ ID NO: 75].

### Claim 3 (depends on 1)

Polynucleotide according to claim 1, consisting of the nucleotide sequence comprised between nucleotide 26,064,934 and nucleotide 26,573,344 of human chromosome 21 (NCBI35:21:26064934:26573344:1) [SEQ ID NO: 76].

### Claim 4 (depends on 1)

Polynucleotide according to claim 1, wherein said hAPP gene is flanked at its 5′ end (in relation to the origin and the direction of the APP gene transcription) by a first nucleotide sequence and at its 3′ end (in relation to the end and the direction of the APP gene transcription) by a second nucleotide sequence, wherein:
said first nucleotide sequence comprises the nucleotide sequence comprised between nucleotide 26,464,810 and nucleotide 26,642,665 of human chromosome 21 (NCBI35:21:26464810:26642665:1) [SEQ ID NO: 77], or a fragment thereof comprising at least one unique sequence, and
said second nucleotide sequence comprises consists by the nucleotide sequence comprised between nucleotide 26,064,934 and nucleotide 26,174,732 of human chromosome 21 (NCBI35:21:26064934:26174732:1) [SEQ ID NO: 78], or a fragment thereof comprising at least one unique sequence.

### Claim 5 (depends on 4)

Polynucleotide according to claim 4, wherein:
said first nucleotide sequence comprises the nucleotide sequence comprised between nucleotide 26,464,810 and nucleotide 26,573,344 of human chromosome 21 (NCBI35:21:26464810:26573344:1) [SEQ ID NO: 79], or a fragment thereof comprising at least one unique sequence, and
said second nucleotide sequence comprises the nucleotide sequence comprised between nucleotide 26,064,934 and nucleotide 26,174,732 of human chromosome 21 (NCBI35:21:26064934:26174732:1) [SEQ ID NO: 78], or a fragment thereof comprising at least one unique sequence.

### Claim 6 (depends on 4)

Polynucleotide according to claim 4, wherein said first nucleotide sequence comprises the nucleotide sequence comprised between nucleotide 26,571,876 and nucleotide 26,573,344 of human chromosome 21 (NCBI35:21:26571876:26573344:1)[SEQ ID NO: 80].

### Claim 7 (depends on 4)

Polynucleotide according to claim 4, wherein said second nucleotide sequence comprises the nucleotide sequence comprised between nucleotide 26,064,934 and nucleotide 26,067,221 of human chromosome 21 (NCBI35:21:26064934:26067221:1) [SEQ ID NO: 81].

### Claim 8 (depends on 1)

A vector comprising a polynucleotide according to claim 1.

### Claim 9 (depends on 8)

Vector according to claim 8, selected from the group formed by a YAC (yeast artificial chromosome), a BAC (bacterial artificial chromosome) or a PAC (P1-derived artificial chromosome).

### Claim 10 (depends on 8)

Vector according to claim 8, wherein said polynucleotide is flanked at one of its ends by a third nucleotide sequence and at the other opposite end by a fourth nucleotide sequence, wherein:
said third nucleotide sequence comprises (i) a telomere functional in yeast cells and at least (ii) one auxotrophic selection marker, and
said fourth nucleotide sequence comprises (i) a centromere functional in yeast cells, a telomere functional in yeast cells and at least one auxotrophic selection marker.

### Claim 11 (depends on 10)

Vector according to claim 10, wherein said auxotrophic selection marker is selected from the group comprised between TRP1, LEU2, LYS2, HIS3, HIS5, TRP1, URA3.

### Claim 12 (depends on 1)

A cell comprising a polynucleotide according to claim 1.

### Claim 13 (depends on 1)

A transgenic non-human animal containing a polynucleotide according to claim 1 inserted in the genome thereof.

### Claim 14 (depends on 13)

Transgenic animal according to claim 13, wherein said animal is a mammal selected from the group consisting of a mouse and a rat.

### Claim 15 (depends on 13)

Transgenic animal according to claim 13, the genome of which further contains one or more molecular markers of Alzheimer's disease.

### Claim 16 (depends on 15)

Transgenic animal according to claim 15, wherein said molecular markers of Alzheimer's disease are selected from the group consisting of the PS1 genes, the PS2 genes and the epsilon4 (ε4) allele of the APOE gene.

### Claim 17 (depends on 13)

A method of studying Alzheimer's disease using a transgenic non-human animal according to claim 13.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 13)

Transgenic animal according to claim 13, wherein said animal expresses only the hAPP gene.

### Claim 21 (depends on 13)

A method for identifying a potentially useful compound for the treatment and/or prevention of Alzheimer's disease, comprising the steps of:
a) administering a candidate compound to a transgenic non-human animal according to claim 13;
b) determining the expression pattern of the hAPP gene and/or the hAPP protein production and/or the β-amyloid (Aβ) peptide production in said transgenic non-human animal of step (a), and
c) selecting the candidate compound causing (i) a decrease in the hAPP gene expression levels in nervous tissue, (ii) a decrease of hAPP protein production and/or accumulation and/or (iii) a decrease in Aβ peptide production and/or accumulation in said transgenic non-human animal

### Claim 22

The offspring of a transgenic non-human animal endogenously expressing the human APP gene with an expression pattern similar or equivalent to the expression pattern of said gene in humans.

### Claim 23 (depends on 8)

A cell comprising a vector according to claim 8.
